Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions

This publication has 163 references indexed in Scilit:

• Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma
  The Laryngoscope, 2012
• Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
  Investigational New Drugs, 2012
• Gene expression profiling on pre‐ and post‐erlotinib tumors from patients with head and neck squamous cell carcinoma
  Head & Neck, 2012
• The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab–bevacizumab–irradiation combination on head and neck cancer xenografts
  Oral Oncology, 2011
• Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma
  Cancer, 2010
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
  The Lancet Oncology, 2010
• Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
  Cancer Cell, 2010
• Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
  Cancer Immunology, Immunotherapy, 2009
• Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
  The Lancet Oncology, 2009
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
  Cancer Cell, 2005